LLY

1,088.54

-1.49%↓

JNJ

206.8

-0.45%↓

ABBV

225.94

-0.7%↓

UNH

330.23

+0.17%↑

AZN

92.45

-0.99%↓

LLY

1,088.54

-1.49%↓

JNJ

206.8

-0.45%↓

ABBV

225.94

-0.7%↓

UNH

330.23

+0.17%↑

AZN

92.45

-0.99%↓

LLY

1,088.54

-1.49%↓

JNJ

206.8

-0.45%↓

ABBV

225.94

-0.7%↓

UNH

330.23

+0.17%↑

AZN

92.45

-0.99%↓

LLY

1,088.54

-1.49%↓

JNJ

206.8

-0.45%↓

ABBV

225.94

-0.7%↓

UNH

330.23

+0.17%↑

AZN

92.45

-0.99%↓

LLY

1,088.54

-1.49%↓

JNJ

206.8

-0.45%↓

ABBV

225.94

-0.7%↓

UNH

330.23

+0.17%↑

AZN

92.45

-0.99%↓

Inicio・Lista de Acciones・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Abierto

SectorSalud

35.23 -0.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

35.08

Máximo

35.52

Métricas clave
By Trading Economics
Ingresos	11M 51M
Ventas	39M 239M
P/B Media del Sector	11.126 79.874
BPA	1.08
Margen de beneficio	21.242
Empleados	268
EBITDA	14M 73M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+30.16% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	344M 2B
Apertura anterior	35.77
Cierre anterior	35.23

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

349 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

29.8 / N/A Soporte y Resistencia

Harmony Biosciences Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 nov 2025, 16:49 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Adquisiciones, fusiones, absorciones

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Charlas de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Charlas de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Adquisiciones, fusiones, absorciones

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Charlas de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Charlas de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Charlas de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Charlas de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Charlas de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Charlas de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Charlas de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Ganancias

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Ganancias

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Ganancias

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Ganancias

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Ganancias

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Ganancias

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Ganancias

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Ganancias

Genting Bhd 3Q EPS MYR0.0079

Comparación entre iguales

Cambio de precio

Harmony Biosciences Holdings Inc Esperado

Precio Objetivo

By TipRanks

30.16% repunte

Estimación a 12 meses

Media 46 USD 30.16%

Máximo 62 USD

Mínimo 32 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

29.8 / N/ASoporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

349 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.